Albireo Pharma Inc Market cap
What is the Market cap of Albireo Pharma Inc?
The Market cap of Albireo Pharma Inc is $492.28M
What is the definition of Market cap?
Market capitalization is the market value at a point in time of the shares outstanding of a publicly traded company, being equal to the share price at that point of time times the number of shares outstanding.
= outstanding shares * previous day’s close
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Market cap of companies in the Health Care sector on NASDAQ compared to Albireo Pharma Inc
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Companies with market cap similar to Albireo Pharma Inc
- NOCIL has Market cap of $491.44M
- Nektar Therapeutics has Market cap of $491.50M
- Tejon Ranch Co has Market cap of $491.61M
- Sisram Medical Ltd has Market cap of $491.70M
- enCore has Market cap of $491.81M
- Garrett Motion Inc has Market cap of $491.97M
- Albireo Pharma Inc has Market cap of $492.28M
- Brasilagro Companhia Brasileira De Propriedade Agricola has Market cap of $492.33M
- Premier Gold Mines has Market cap of $493.21M
- Beijing Enterprises Clean has Market cap of $493.64M
- Xinyuan Ppty Mgmt Svc has Market cap of $493.73M
- IQE Plc has Market cap of $494.04M
- South Plains Inc has Market cap of $494.72M